Artisan Mid Cap Value Fund Increased its Stake in ICON Public Limited Company (ICLR). Here’s Why

Group 1: Artisan Mid Cap Value Fund Performance - Artisan Mid Cap Value Fund's Investor Class fund ARTQX returned 0.97%, Advisor Class fund APDQX posted a return of 0.98%, and Institutional Class fund APHQX returned 0.97% in Q3 2025, compared to a 6.18% return for the Russell Midcap Value Index [1] - The equity markets continued to rally in Q3 2025, driven by strong corporate earnings, rising AI capital expenditures, and expectations for economic support from US fiscal policy and lower interest rates [1] Group 2: ICON Public Limited Company Overview - ICON Public Limited Company (NASDAQ:ICLR) is the second-largest global contract research organization (CRO), providing outsourced clinical development services to the pharmaceutical and biotechnology industries [3] - The one-month return for ICON was 3.61%, while its shares lost 12.45% over the last 52 weeks, closing at $188.67 per share on January 2, 2026, with a market capitalization of $14.673 billion [2] Group 3: Market Conditions and Outlook for ICON - The life sciences, pharma, and biotech sectors have faced weakness over the past year, but positive earnings reports from ICON and other CROs suggest that biopharma demand may be bottoming [3] - The biopharma funding environment has been challenging due to higher interest rates and macroeconomic uncertainty, leading to cautious decision-making among pharma and biotech companies [3] - The current market conditions present an opportunity to build a position in ICON, which is expected to generate mid- to high-single-digit revenue growth in a normalized environment and gain market share in a fragmented industry [3] - ICON is trading at just 13X forward earnings, near its cheapest levels since the 2008–2009 global financial crisis, making the risk/reward profile attractive [3]